Respiratory healthtech startup Resmonics closes its pre-seed financing round
19.01.2021
Recently incorporated digital biomarker startup Resmonics has received financial support from the CSS Insurance in its pre-seed financing round. The due diligence was conducted by Redstone on behalf of CSS Insurance. The funding will be used to accelerate the development of its first product, a smartphone-based digital biomarker service for patients suffering from asthma or COPD, and to certify it as a medical device.
12.jpg) |
 |
With the secured investment from CSS, Resmonics plans to enter the Swiss and European market in Q3/21. In return for its investment, CSS Insurance will take a minority stake in Resmonics. Both parties set up the deal with the goal of facilitating Resmonics' long-term growth by remaining an attractive investment opportunity for new investors in future fundraising rounds.
“We are very excited to have attracted CSS Insurance, one of the leading players in the Swiss healthcare market, as our first investor,” says Peter Tinschert, CEO and Co-Founder of Resmonics. “Their profound understanding of the evolving digital health market and strong network puts us in a unique position to grow Resmonics beyond the Swiss market.”
(Press release)
“We are very excited to have attracted CSS Insurance, one of the leading players in the Swiss healthcare market, as our first investor,” says Peter Tinschert, CEO and Co-Founder of Resmonics. “Their profound understanding of the evolving digital health market and strong network puts us in a unique position to grow Resmonics beyond the Swiss market.”
(Press release)